Since 2012, TriLink has been the industry leader in custom mRNA synthesis for research and clinical applications, with more than 975 completed programs. Now is your opportunity to leverage TriLink’s mRNA innovations and expertise, including its proprietary CleanCap® technology, CleanScript™ technology of in vitro transcription (IVT) methods and protocols optimized to reduce dsRNA, standard and custom NTP portfolios, and leading-edge analytical and QC methods.
When you partner with TriLink for custom mRNA synthesis, your research or discovery program is supported by a dedicated team of process development and manufacturing experts with a legacy of mRNA experience. Our process development scientists will support your program and leverage TriLink’s optimized in vitro transcription and purification processes to meet the unique needs of your drug discovery research and development program.
TriLink’s proprietary mRNA synthesis capabilities include CleanScript™ in vitro transcription method optimized to decrease dsRNA, scales ranging from milligram to multi-gram, and lengths ranging from a few hundred nucleotides to over 14 kilobases. Additionally, TriLink’s proprietary CleanCap® capping technology achieves highly efficient and economical co-transcriptional mRNA capping with fewer processing steps. TriLink’s mRNA manufacturing services teams provide consultative support throughout the design and optimization processes, working collaboratively with you to design and produce the mRNA you seek.
TriLink also offers customization of its proprietary purification processes suitable for your application. Purification options include DNase-treatments, silica membrane purification, Oligo dT capture, and high-performance liquid chromatography.
TriLink’s analytical testing and QC assay capabilities to support mRNA programs include identity, characterization, impurity, and safety testing. Our expert analytical services team also offers construct-specific assays and method development.
Design your mRNA or long RNA transcript using TriLink's mRNAbuilder™. Upon submission, our Technical Support team will review and provide a quotation within 3-5 business days. Our team of mRNA experts is here to help you with any questions, or to discuss your mRNA synthesis needs.
Our pre-designed, stocked mRNAs resemble fully processed, capped, and polyadenylated mRNAs ready for translation by the ribosome.
CleanCap® technology provides optimized co-transcriptional capping for vaccine and therapeutic and diagnostic applications as well as for cell and gene therapies and protein engineering applications.
Our manufacturing processes are scalable to support your program as you progress to preclinical through clinical development.
Blog post: Perspectives on In Vitro Transcription (IVT) mRNA Sequence Optimization
Blog post: Optimizing the Performance of IVT mRNA Using N1-Methylpseudouridine (N1mΨ)—Part 1
Webinar: Streamlined mRNA Synthesis for Increased Protein Expression-TIDES Digital Week
Poster: CleanCap® Co-transcriptional Capping Streamlines mRNA Manufacturing